Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bluelinea S.A. (ALBLU.PA)
Versailles, FR
Bluelinea Société Anonyme, established in 2006 and based in Elancourt, France, specializes in delivering a variety of healthcare solutions to support elderly and disabled individuals across France. Their comprehensive product portfolio encompasses SERENEA, a dedicated nursing call system, and BluePhone, a mobile device offering remote assistance specifically for seniors. The company also provides the BlueGard geolocation bracelet and items designed to prevent night falls. Furthermore, Bluelinea offers advanced home automation solutions for environmental management, automated entry systems, and intercom/videophone capabilities, alongside fall and smoke detectors, emergency call watches, and secure key storage options. Additional provisions include BlueHub bundles, Handi Joysticks, IP-based nurse call systems, anti-elopement controls, independence-monitoring bracelets, infant protection products, paging devices, and EHPADOM counters.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.49% | +1.99% | -10.87% | -16.33% | -19.61% | -16.33% | -43.84% | -72.11% | -90.53% | -94.65% | -91.80% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+10.1% Q4'25: +1.4% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+18.2% Q4'25: -15.4% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-12.4% Q4'25: -7.5% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-12.6% Q4'25: -13.6% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%-24.5% Q4'25: -49.6% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+50.0% Q4'25: +50.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×4.19× Q4'25: 2.54× (vs Q4'23)
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
|---|---|---|---|---|---|---|
| Revenue |
6.16M
est: 6.26M (-1.6%)
|
6.31M
est: 6.46M (-2.5%)
|
6.83M
est: 7.87M (-13.3%)
|
7.52M
est: 9.56M (-21.3%)
|
10.41M
est: 11.45M (-9.1%)
|
9.88M
est: 13.92M (-29.0%)
|
| EBITDA |
-1.81M
est: -608.2K (-197.5%)
|
-1.72M
est: -615.6K (-179.5%)
|
-1.63M
est: -749.2K (-117.2%)
|
-2.62M
est: -910.0K (-187.7%)
|
74.4K
est: -4.45M (+101.7%)
|
98.2K
est: -1.36M (+107.2%)
|
| EBIT |
-3.18M
est: -1.70M (-86.8%)
|
-3.15M
est: -1.72M (-83.1%)
|
-3.00M
est: -2.10M (-43.1%)
|
-3.64M
est: -2.54M (-43.0%)
|
-1.40M
est: -5.70M (+75.4%)
|
-1.70M
est: -3.80M (+55.3%)
|
| Net Income |
-2.74M
est: -6.58M (+58.4%)
|
-2.79M
est: -6.73M (+58.6%)
|
-2.70M
est: 623.3K (-533.3%)
|
-3.30M
est: 4.24M (-177.9%)
|
-1.54M
est: -5.01M (+69.2%)
|
-1.62M
est: 47.20M (-103.4%)
|
| SGA |
60.6K
est: 96.5K (-37.2%)
|
64.2K
est: 97.6K (-34.2%)
|
72.1K
est: 121.2K (-40.5%)
|
396.8K
est: 147.2K (+169.5%)
|
142.9K
est: 176.3K (-18.9%)
|
—
est: 214.4K (-100.0%)
|
| EPS |
-0.50
est: -0.54 (+6.6%)
|
-0.51
est: -0.56 (+8.3%)
|
-0.46
est: 0.05 (-993.2%)
|
-0.54
est: 0.35 (-254.2%)
|
-0.12
est: 1.14 (-110.5%)
|
0.00
est: 3.82 (-100.0%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adrien Westermann | Director of E-Commerce & Member of Management Board | — | male |
| David Guyard | Director of R&D and Member of Management Board | — | male |
| Eric Gbianza | Chief Financial Officer & Member of Management Board | — | male |
| Laurent Levasseur | Chairman of the Executive Board | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ALBLU.PA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
